Plasma amyloid‐β40/42 ratio can distinguish co‐morbid Alzheimer’s disease pathology in patients with Lewy body disease Authors: Moeko Shinohara, Hidetomo Murakami, Yasuhiro Sakashita, Yukiko Mori, Junji Komatsu, Daiki Muramatsu, Sadao Hikishima, Kenjiro Ono Published: 2025 ABSTRACT AbstractBackgroundAlthough comorbidity with Alzheimer’s disease (AD) is not uncommon in Lewy body disease (LBD), no blood biomarkers which can identify AD pathology in LBD have ever been established.ObjectivesTo investigate if plasma amyloid‐β (Aβ) biomarkers can distinguish AD comorbidity in LBD patients.MethodsWe examined plasma Aβ40, and Aβ42 in 15 patients with Aβ negative LBD, 10 with Aβ positive LBD, and 37 with AD. In addition, patients underwent amyloid‐positron emission tomography imaging (11C Pittsburgh compound‐B) or cerebrospinal fluid Aβ42 test.ResultsThe plasma Aβ40/Aβ42 ratio was significantly decreased in patients with Aβ+ LBD compared with those with Aβ‐ LBD (p = 0.037) and could accurately classify the two diseases (area under the curve, 0.727).ConclusionsPlasma Aβ40/Aβ42 ratio might be a useful marker for comorbid AD pathology in LBD.